Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/16111
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
StatisticsItem usage statistics
MetadataShow Dublin Core item record
Document typeresearch article
CitationNadal E, Bosch-Barrera J, Cedres S, Coves J, Garcia-Campelo R, Guirado M, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. Epub 2021 Feb 4.
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.